Anil Potti and his former Duke colleagues have retracted a sixth paper, this one in PLoS ONE.
According to the retraction notice for “An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer,” the withdrawal was prompted by the retraction of a Nature Medicine paper that formed the basis of the PLoS ONE study’s approach: Continue reading Potti retraction tally grows to six with a withdrawal in PLoS ONE, and will likely end up near a dozen
Scott Weber, the nursing researcher accused of manipulating references and other publishing misconduct in at least seven retracted articles, has lost his position at Walden University, Retraction Watch has learned.
We noticed the other day that Weber’s name had disappeared from the Walden website and put in a call to the institution. A source there told us that Weber — a part-time faculty member who had been hoping for a full-time appointment at the school — apologized when confronted about the fraud.
The source, who did not want to be identified, said Continue reading Publishing scandal costs nursing researcher his post at online university
Ten days ago, we reported on the dismissal of Zhiguo Wang, a Montreal Heart Institute researcher who had already retracted two papers because of image manipulation. At the time, an official said the institute had requested three more retractions, but when we asked which three papers, we were told:
As written in the press release, the MHI has requested the retraction of three additional scientific articles. We will not be able to confirm the name of the scientific articles and/or publications until confirmation of the retractions.
The first of those three has now appeared, in the Journal of Cell Science, for the 2007 paper, “The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes.” According to the retraction notice — which is unfortunately behind a paywall (see update at end): Continue reading Third retraction from dismissed Montreal cardiology researcher Zhiguo Wang appears
The authors of a 2010 Journal of Immunology paper have retracted it, saying that part of one of the figures was actually a placeholder from another experiment.
According to the retraction notice for “Stimulation of FcgRI on Primary Sensory Neurons Increases Insulin-Like Growth Factor-I Production, Thereby Reducing Reperfusion-Induced Renal Injury in Mice” by Naoaki Harada, Juan Zhao, Hiroki Kurihara, Naomi Nakagata, and Kenji Okajima: Continue reading Group under investigation retracts second paper, claims errant figure was just a placeholder
Last week, we reported on an uniformative retraction notice in Molecular Biology and Evolution (MBE), an Oxford University Press (OUP) title, that the publisher wanted $32 to read. To OUP’s credit, they quickly acknowledged that the retraction hadn’t been handled properly.
Earlier this week, OUP’s senior publisher for journals Cathy Kennedy followed up with some welcome news: Continue reading Oxford University Press clarifies policy: All retraction notices will be open access
We can only imagine how Joe Hollyfield felt to learn from us, of all people, that his journal, Experimental Eye Research, had retracted two manuscripts in a recent issue.
The papers, “Mechanisms of retinal ganglion cell injury and defense in glaucoma,” by Qu J, Wang D, and Grosskreutz CL, and “Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma,” by Osborne, NN, carried the same retraction notices:
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Because in our experience such unhelpful wording often masks interesting details — read, author misconduct — we called Hollyfield for comment. He graciously walked us through the retractions, explaining the case in detail, until we realized that we were talking about different papers entirely. Hollyfield, it turned out, thought we were asking about the travails of Sangiliyandi Gurunathan, an eye researcher from India whom we’d previously covered and whose work recently had been retracted by Experimental Eye Research and other journals for image manipulation.
But Hollyfield was unaware of the two retractions we’d intended to talk about with him and told us he’d look into them.
Here’s what he learned: Continue reading Publisher error handling two eye papers leads to retractions, new policy on notices
Tilburg University in the Netherlands has suspended the prominent social psychologist Diederik Stapel over concerns that he fabricated data in his published studies. According to a translation of a press release from the school, Stapel, professor of cognitive social psychology and dean of Tilburg’s School of Social and Behavioral Sciences, “has committed a serious breach of scientific integrity by using fictitious data in his publications.”
The release says the rector of Tilburg has set up a committee to investigate Stapel’s manuscripts and report back by October. Heading the panel is W.J.M. Levelt, former* president of the Royal Dutch Academy of Sciences and professor emeritus at the Radboud University in Nijmegen.
What the release does not specify, however, is which of Stapel’s many publications — a Medline search comes up with at least 45 bearing his name — are implicated. Continue reading Dutch university investigating psych researcher Stapel for data fraud
Anil Potti, the former cancer researcher whose work has become the subject of intense scrutiny that has already led to the retraction of five papers, didn’t tell the Journal of the American Medical Association (JAMA) about two very relevant corporate relationships he had when he published papers there, Retraction Watch has learned.
JAMA has published two papers by Potti and colleagues: 2008’s “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” and 2010’s “Age- and Sex-Specific Genomic Profiles in Non-Small Cell Lung Cancer.”
The Cancer Letter, which has been way out front in the Potti case, first reported Potti’s relationships with Eli Lilly and CancerGuide Diagnostics (formerly Oncogenomics, Inc.). As The Chronicle, Duke’s student newspaper, reported last September, the two companies cut their ties with Potti in July 2010 after allegations of misconduct and lying about a Rhodes Scholarship came to light.
But that was after the two papers were published, and Potti had relationships with both since 2006. As The Chronicle notes, he was a director at CancerGuide Diagnostics (formerly Oncogenomics, Inc.), and Continue reading Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers
Sometime last year, the University of Zurich’s Erik Postma was reading a paper in Science titled “Additive Genetic Breeding Values Correlate with the Load of Partially Deleterious Mutations” when he realized something.
The authors, led by Joseph Tomkins of the University of Western Australia, had made a mistake.
Postma set to writing a “Technical Comment,” the way that Science usually deals with criticism of a paper’s methods. He sent his first draft to the Tomkins group: Continue reading Science genetics paper retracted after “unfortunate mistake”
A Montreal Heart Institute researcher who retracted two papers less than a month ago has been fired from his post.
Zhiguo Wang, who had been funded by the Canadian Institute of Health Research and the Canadian Diabetes Association, studied the genes linked to heart rhythm abnormalities, among other subjects. Wang also has an appointment at the University of Montreal.
As first reported in Retraction Watch, Wang withdrew two papers for the Journal of Biological Chemistry (JBC) in the journal’s August 12 issue. The story was quickly picked up by Postmedia and the CBC. At the time, Wang told us: Continue reading Montreal Heart Institute researcher dismissed following two retractions for image manipulation